Contact
searchSearch
HMP Global
Login

Liver Cancer Specialty Channel

Liver Cancer
Specialty Channel
Conference Coverage
Lenvatinib Plus Pembrolizumab Added to TACE Significantly Improves PFS in Intermediate-Stage Hepatocellular Carcinoma: LEAP-012
09/14/2024
The LEAP-012 trial met its primary end point demonstrating a statistically significant and clinically meaningful improvement in PFS with the addition of lenvatinib plus pembrolizumab to TACE for patients with intermediate-stage hepatocellular...
The LEAP-012 trial met its primary end point demonstrating a statistically significant and clinically meaningful improvement in PFS with the addition of lenvatinib plus pembrolizumab to TACE for patients with intermediate-stage hepatocellular...
The LEAP-012 trial met its...
09/14/2024
Oncology
FDA Approval
FDA Approves Subcutaneous Formulation of Atezolizumab for Patients With Certain Solid Tumors
09/13/2024
On September 12th, 2024, the US FDA approved subcutaneous coformulation of atezolizumab plus hyaluronidase for adult patients with non-small cell lung cancer, small cell lung cancer, hepatocellular carcinoma, melanoma, and alveolar soft part...
On September 12th, 2024, the US FDA approved subcutaneous coformulation of atezolizumab plus hyaluronidase for adult patients with non-small cell lung cancer, small cell lung cancer, hepatocellular carcinoma, melanoma, and alveolar soft part...
On September 12th, 2024, the US...
09/13/2024
Oncology
News
Bevacizumab-Erlotinib Switch Maintenance Improved Progression-Free Survival Among Patients With Advanced Biliary Tract Cancers
08/26/2024
According to results from a phase 2/3 study, bevacizumab-erlotinib switch maintenance improved progression-free survival among patients with chemotherapy-responsive advanced biliary tract cancers.
According to results from a phase 2/3 study, bevacizumab-erlotinib switch maintenance improved progression-free survival among patients with chemotherapy-responsive advanced biliary tract cancers.
According to results from a...
08/26/2024
Oncology
News
Sorafenib Plus Transarterial Chemoembolization Improves Survival Outcomes, Response Among Patients With Recurrent Hepatocellular Carcinoma
07/29/2024
According to a phase 3 trial, the addition of sorafenib to TACE improved survival outcomes and response among patients with recurrent intermediate-stage hepatocellular carcinoma after R0 initial hepatectomy and microvascular invasion.
According to a phase 3 trial, the addition of sorafenib to TACE improved survival outcomes and response among patients with recurrent intermediate-stage hepatocellular carcinoma after R0 initial hepatectomy and microvascular invasion.
According to a phase 3 trial,...
07/29/2024
Oncology
News
Laparoscopic Hemihepatectomy vs Open Hemihepatectomy Among Patients With Primary or Metastatic Liver Tumors
05/17/2024
Stephanie Holland
Results from the ORANGE II PLUS trial demonstrated that a minimally invasive, laparoscopic approach to hemihepatectomy shortened time to functional recovery compared to open, major hemihepatectomy among patients with primary or metastatic...
Results from the ORANGE II PLUS trial demonstrated that a minimally invasive, laparoscopic approach to hemihepatectomy shortened time to functional recovery compared to open, major hemihepatectomy among patients with primary or metastatic...
Results from the ORANGE II PLUS...
05/17/2024
Oncology
Conference Coverage
Adding Durvalumab, Bevacizumab to TACE Improved Progression-Free Survival Among Patients With Unresectable Hepatocellular Carcinoma
01/19/2024
According to results from the phase 3 EMERALD-1 trial, adding durvalumab and bevacizumab to transarterial chemoembolization improved the progression-free survival among patients with hepatocellular carcinoma.
According to results from the phase 3 EMERALD-1 trial, adding durvalumab and bevacizumab to transarterial chemoembolization improved the progression-free survival among patients with hepatocellular carcinoma.
According to results from the...
01/19/2024
Oncology
News
Antiviral Therapy Found to Improve Long-Term Survival for Patients With HBV- and HCV-Related Hepatocellular Carcinoma
01/12/2024
According to a retrospective study, antiviral therapy is associated with long-term survival among patients with hepatitis B virus (HBV)- or hepatitis C virus (HCV)-related hepatocellular carcinoma who undergo curative resection but is...
According to a retrospective study, antiviral therapy is associated with long-term survival among patients with hepatitis B virus (HBV)- or hepatitis C virus (HCV)-related hepatocellular carcinoma who undergo curative resection but is...
According to a retrospective...
01/12/2024
Oncology
News
Proton Beam Radiotherapy as Treatment Alternative to TACE for Patients With Hepatocellular Carcinoma
08/10/2023
According to a randomized trial, proton beam radiotherapy may be a viable treatment alternative to transarterial chemoembolization for patients with hepatocellular carcinoma.
According to a randomized trial, proton beam radiotherapy may be a viable treatment alternative to transarterial chemoembolization for patients with hepatocellular carcinoma.
According to a randomized trial,...
08/10/2023
Oncology
News
Clinicopathological Differences Between Resected Hepatocellular Carcinoma Caused by NAFLD/NASH and Other Etiologies
03/24/2023
In this retrospective analysis, patients with NAFLD/NASH-related hepatocellular carcinoma were found to be more likely to have larger tumors and to lack background liver fibrosis.
In this retrospective analysis, patients with NAFLD/NASH-related hepatocellular carcinoma were found to be more likely to have larger tumors and to lack background liver fibrosis.
In this retrospective analysis,...
03/24/2023
Oncology
Conference Coverage
Tislelizumab Yields Better Health-Related Quality of Life Outcomes vs Sorafenib for Patients With Unresectable Hepatocellular Carcinoma
01/20/2023
Patients with hepatocellular carcinoma treated with tislelizumab had better health-related quality of life outcomes compared to those treated with sorafenib, according to results presented at the 2023 ASCO Gastrointestinal Cancers Symposium.
Patients with hepatocellular carcinoma treated with tislelizumab had better health-related quality of life outcomes compared to those treated with sorafenib, according to results presented at the 2023 ASCO Gastrointestinal Cancers Symposium.
Patients with hepatocellular...
01/20/2023
Oncology
News
FDA Approves Tremelimumab Plus Durvalumab for Unresectable Hepatocellular Carcinoma
10/26/2022
The FDA granted approval to tremelimumab in combination with durvalumab for patients with unresectable hepatocellular carcinoma, based on findings from the phase 3 HIMALAYA trial.
The FDA granted approval to tremelimumab in combination with durvalumab for patients with unresectable hepatocellular carcinoma, based on findings from the phase 3 HIMALAYA trial.
The FDA granted approval to...
10/26/2022
Oncology

News

Conference Coverage
Lenvatinib Plus Pembrolizumab Added to TACE Significantly Improves PFS in Intermediate-Stage Hepatocellular Carcinoma: LEAP-012
09/14/2024
The LEAP-012 trial met its primary end point demonstrating a statistically significant and clinically meaningful improvement in PFS with the addition of lenvatinib plus pembrolizumab to TACE for patients with intermediate-stage hepatocellular...
The LEAP-012 trial met its primary end point demonstrating a statistically significant and clinically meaningful improvement in PFS with the addition of lenvatinib plus pembrolizumab to TACE for patients with intermediate-stage hepatocellular...
The LEAP-012 trial met its...
09/14/2024
Oncology
FDA Approval
FDA Approves Subcutaneous Formulation of Atezolizumab for Patients With Certain Solid Tumors
09/13/2024
On September 12th, 2024, the US FDA approved subcutaneous coformulation of atezolizumab plus hyaluronidase for adult patients with non-small cell lung cancer, small cell lung cancer, hepatocellular carcinoma, melanoma, and alveolar soft part...
On September 12th, 2024, the US FDA approved subcutaneous coformulation of atezolizumab plus hyaluronidase for adult patients with non-small cell lung cancer, small cell lung cancer, hepatocellular carcinoma, melanoma, and alveolar soft part...
On September 12th, 2024, the US...
09/13/2024
Oncology
News
Bevacizumab-Erlotinib Switch Maintenance Improved Progression-Free Survival Among Patients With Advanced Biliary Tract Cancers
08/26/2024
According to results from a phase 2/3 study, bevacizumab-erlotinib switch maintenance improved progression-free survival among patients with chemotherapy-responsive advanced biliary tract cancers.
According to results from a phase 2/3 study, bevacizumab-erlotinib switch maintenance improved progression-free survival among patients with chemotherapy-responsive advanced biliary tract cancers.
According to results from a...
08/26/2024
Oncology
News
Sorafenib Plus Transarterial Chemoembolization Improves Survival Outcomes, Response Among Patients With Recurrent Hepatocellular Carcinoma
07/29/2024
According to a phase 3 trial, the addition of sorafenib to TACE improved survival outcomes and response among patients with recurrent intermediate-stage hepatocellular carcinoma after R0 initial hepatectomy and microvascular invasion.
According to a phase 3 trial, the addition of sorafenib to TACE improved survival outcomes and response among patients with recurrent intermediate-stage hepatocellular carcinoma after R0 initial hepatectomy and microvascular invasion.
According to a phase 3 trial,...
07/29/2024
Oncology
News
Laparoscopic Hemihepatectomy vs Open Hemihepatectomy Among Patients With Primary or Metastatic Liver Tumors
05/17/2024
Stephanie Holland
Results from the ORANGE II PLUS trial demonstrated that a minimally invasive, laparoscopic approach to hemihepatectomy shortened time to functional recovery compared to open, major hemihepatectomy among patients with primary or metastatic...
Results from the ORANGE II PLUS trial demonstrated that a minimally invasive, laparoscopic approach to hemihepatectomy shortened time to functional recovery compared to open, major hemihepatectomy among patients with primary or metastatic...
Results from the ORANGE II PLUS...
05/17/2024
Oncology
Conference Coverage
Adding Durvalumab, Bevacizumab to TACE Improved Progression-Free Survival Among Patients With Unresectable Hepatocellular Carcinoma
01/19/2024
According to results from the phase 3 EMERALD-1 trial, adding durvalumab and bevacizumab to transarterial chemoembolization improved the progression-free survival among patients with hepatocellular carcinoma.
According to results from the phase 3 EMERALD-1 trial, adding durvalumab and bevacizumab to transarterial chemoembolization improved the progression-free survival among patients with hepatocellular carcinoma.
According to results from the...
01/19/2024
Oncology
News
Antiviral Therapy Found to Improve Long-Term Survival for Patients With HBV- and HCV-Related Hepatocellular Carcinoma
01/12/2024
According to a retrospective study, antiviral therapy is associated with long-term survival among patients with hepatitis B virus (HBV)- or hepatitis C virus (HCV)-related hepatocellular carcinoma who undergo curative resection but is...
According to a retrospective study, antiviral therapy is associated with long-term survival among patients with hepatitis B virus (HBV)- or hepatitis C virus (HCV)-related hepatocellular carcinoma who undergo curative resection but is...
According to a retrospective...
01/12/2024
Oncology
News
Proton Beam Radiotherapy as Treatment Alternative to TACE for Patients With Hepatocellular Carcinoma
08/10/2023
According to a randomized trial, proton beam radiotherapy may be a viable treatment alternative to transarterial chemoembolization for patients with hepatocellular carcinoma.
According to a randomized trial, proton beam radiotherapy may be a viable treatment alternative to transarterial chemoembolization for patients with hepatocellular carcinoma.
According to a randomized trial,...
08/10/2023
Oncology
News
Clinicopathological Differences Between Resected Hepatocellular Carcinoma Caused by NAFLD/NASH and Other Etiologies
03/24/2023
In this retrospective analysis, patients with NAFLD/NASH-related hepatocellular carcinoma were found to be more likely to have larger tumors and to lack background liver fibrosis.
In this retrospective analysis, patients with NAFLD/NASH-related hepatocellular carcinoma were found to be more likely to have larger tumors and to lack background liver fibrosis.
In this retrospective analysis,...
03/24/2023
Oncology
Conference Coverage
Tislelizumab Yields Better Health-Related Quality of Life Outcomes vs Sorafenib for Patients With Unresectable Hepatocellular Carcinoma
01/20/2023
Patients with hepatocellular carcinoma treated with tislelizumab had better health-related quality of life outcomes compared to those treated with sorafenib, according to results presented at the 2023 ASCO Gastrointestinal Cancers Symposium.
Patients with hepatocellular carcinoma treated with tislelizumab had better health-related quality of life outcomes compared to those treated with sorafenib, according to results presented at the 2023 ASCO Gastrointestinal Cancers Symposium.
Patients with hepatocellular...
01/20/2023
Oncology

Interactive Features

Quiz
Quiz: Which options was found to be a potential first-line treatment for hepatocellular carcinoma?
10/17/2022
Do you know which option was found to be a potential first-line treatment for patients with hepatocellular carcinoma following radical resection who had not received any prior systemic cancer therapy? Take our quick quiz to find out.
Do you know which option was found to be a potential first-line treatment for patients with hepatocellular carcinoma following radical resection who had not received any prior systemic cancer therapy? Take our quick quiz to find out.
Do you know which option was...
10/17/2022
Oncology
Quiz
Quiz: Cabozantinib Plus Atezolizumab for Advanced Hepatocellular Carcinoma
09/02/2022
Did cabozantinib plus atezolizumab significantly improve clinically meaningful end points for patients with advanced hepatocellular carcinoma who had not previously received systemic cancer therapy when compared to sorafenib?
Did cabozantinib plus atezolizumab significantly improve clinically meaningful end points for patients with advanced hepatocellular carcinoma who had not previously received systemic cancer therapy when compared to sorafenib?
Did cabozantinib plus...
09/02/2022
Oncology

Recent News

FDA Approval
FDA Approves Subcutaneous Formulation of Atezolizumab for Patients With Certain Solid Tumors
09/13/2024
On September 12th, 2024, the US FDA approved subcutaneous coformulation of atezolizumab plus hyaluronidase for adult patients with non-small cell lung cancer, small cell lung cancer, hepatocellular carcinoma, melanoma, and alveolar soft part...
On September 12th, 2024, the US FDA approved subcutaneous coformulation of atezolizumab plus hyaluronidase for adult patients with non-small cell lung cancer, small cell lung cancer, hepatocellular carcinoma, melanoma, and alveolar soft part...
On September 12th, 2024, the US...
09/13/2024
Oncology
News
Bevacizumab-Erlotinib Switch Maintenance Improved Progression-Free Survival Among Patients With Advanced Biliary Tract Cancers
08/26/2024
According to results from a phase 2/3 study, bevacizumab-erlotinib switch maintenance improved progression-free survival among patients with chemotherapy-responsive advanced biliary tract cancers.
According to results from a phase 2/3 study, bevacizumab-erlotinib switch maintenance improved progression-free survival among patients with chemotherapy-responsive advanced biliary tract cancers.
According to results from a...
08/26/2024
Oncology
News
Sorafenib Plus Transarterial Chemoembolization Improves Survival Outcomes, Response Among Patients With Recurrent Hepatocellular Carcinoma
07/29/2024
According to a phase 3 trial, the addition of sorafenib to TACE improved survival outcomes and response among patients with recurrent intermediate-stage hepatocellular carcinoma after R0 initial hepatectomy and microvascular invasion.
According to a phase 3 trial, the addition of sorafenib to TACE improved survival outcomes and response among patients with recurrent intermediate-stage hepatocellular carcinoma after R0 initial hepatectomy and microvascular invasion.
According to a phase 3 trial,...
07/29/2024
Oncology
News
Laparoscopic Hemihepatectomy vs Open Hemihepatectomy Among Patients With Primary or Metastatic Liver Tumors
05/17/2024
Stephanie Holland
Results from the ORANGE II PLUS trial demonstrated that a minimally invasive, laparoscopic approach to hemihepatectomy shortened time to functional recovery compared to open, major hemihepatectomy among patients with primary or metastatic...
Results from the ORANGE II PLUS trial demonstrated that a minimally invasive, laparoscopic approach to hemihepatectomy shortened time to functional recovery compared to open, major hemihepatectomy among patients with primary or metastatic...
Results from the ORANGE II PLUS...
05/17/2024
Oncology
News
Antiviral Therapy Found to Improve Long-Term Survival for Patients With HBV- and HCV-Related Hepatocellular Carcinoma
01/12/2024
According to a retrospective study, antiviral therapy is associated with long-term survival among patients with hepatitis B virus (HBV)- or hepatitis C virus (HCV)-related hepatocellular carcinoma who undergo curative resection but is...
According to a retrospective study, antiviral therapy is associated with long-term survival among patients with hepatitis B virus (HBV)- or hepatitis C virus (HCV)-related hepatocellular carcinoma who undergo curative resection but is...
According to a retrospective...
01/12/2024
Oncology
News
Proton Beam Radiotherapy as Treatment Alternative to TACE for Patients With Hepatocellular Carcinoma
08/10/2023
According to a randomized trial, proton beam radiotherapy may be a viable treatment alternative to transarterial chemoembolization for patients with hepatocellular carcinoma.
According to a randomized trial, proton beam radiotherapy may be a viable treatment alternative to transarterial chemoembolization for patients with hepatocellular carcinoma.
According to a randomized trial,...
08/10/2023
Oncology
News
Clinicopathological Differences Between Resected Hepatocellular Carcinoma Caused by NAFLD/NASH and Other Etiologies
03/24/2023
In this retrospective analysis, patients with NAFLD/NASH-related hepatocellular carcinoma were found to be more likely to have larger tumors and to lack background liver fibrosis.
In this retrospective analysis, patients with NAFLD/NASH-related hepatocellular carcinoma were found to be more likely to have larger tumors and to lack background liver fibrosis.
In this retrospective analysis,...
03/24/2023
Oncology
News
FDA Approves Tremelimumab Plus Durvalumab for Unresectable Hepatocellular Carcinoma
10/26/2022
The FDA granted approval to tremelimumab in combination with durvalumab for patients with unresectable hepatocellular carcinoma, based on findings from the phase 3 HIMALAYA trial.
The FDA granted approval to tremelimumab in combination with durvalumab for patients with unresectable hepatocellular carcinoma, based on findings from the phase 3 HIMALAYA trial.
The FDA granted approval to...
10/26/2022
Oncology
News
Ramucirumab Safe and Effective for Patients With Hepatocellular Carcinoma With No Prior Sorafenib Treatment
10/07/2022
According to an expansion cohort of a phase 3 trial, ramucirumab was well-tolerated, and demonstrated meaningful clinical activity for previously-treated patients with hepatocellular carcinoma who had not received sorafenib.
According to an expansion cohort of a phase 3 trial, ramucirumab was well-tolerated, and demonstrated meaningful clinical activity for previously-treated patients with hepatocellular carcinoma who had not received sorafenib.
According to an expansion cohort...
10/07/2022
Oncology
News
Transarterial Chemoembolization Added to Lenvatinib Improves Clinical Outcomes in Hepatocellular Carcinoma
09/08/2022
Findings from a phase 3 trial demonstrates that adding transarterial chemoembolization to lenvatinib improves survival and response outcomes vs lenvatinib alone in patients with hepatocellular carcinoma.
Findings from a phase 3 trial demonstrates that adding transarterial chemoembolization to lenvatinib improves survival and response outcomes vs lenvatinib alone in patients with hepatocellular carcinoma.
Findings from a phase 3 trial...
09/08/2022
Oncology
News
Intraoperative Radiation Therapy May Improve Survival For Certain Patients With Recurrent Cervical or Endometrial Cancer
11/14/2024
According to a retrospective study, there was an appreciable survival gain for well-selected patients with recurrent or persistent endometrial or cervical cancer who receive intraoperative radiation therapy.
According to a retrospective study, there was an appreciable survival gain for well-selected patients with recurrent or persistent endometrial or cervical cancer who receive intraoperative radiation therapy.
According to a retrospective...
11/14/2024
Oncology
News
Amrubicin Plus Irinotecan Demonstrates Promising Efficacy, Safety for Chemotherapy-Naïve Patients With Extensive-Disease Small Cell Lung Cancer
11/14/2024
According to results from the phase 2 LC 08-01 trial, amrubicin plus irinotecan demonstrated promising efficacy and safety among chemotherapy-naïve patients with extensive-disease small cell lung cancer.
According to results from the phase 2 LC 08-01 trial, amrubicin plus irinotecan demonstrated promising efficacy and safety among chemotherapy-naïve patients with extensive-disease small cell lung cancer.
According to results from the...
11/14/2024
Oncology
News
Addition of Bempegaldesleukin to Nivolumab Does Not Benefit Cisplatin-Ineligible Patients With First-Line Advanced Urothelial Carcinoma
11/13/2024
Results from the phase 2 PIVOT-10 trial demonstrated that the addition of bempegaldesleukin to first-line nivolumab did not improve outcomes for cisplatin-ineligible patients with locally advanced or metastatic urothelial carcinoma.
Results from the phase 2 PIVOT-10 trial demonstrated that the addition of bempegaldesleukin to first-line nivolumab did not improve outcomes for cisplatin-ineligible patients with locally advanced or metastatic urothelial carcinoma.
Results from the phase 2...
11/13/2024
Oncology
News
Mirdametinib for Adult and Pediatric Patients With Neurofibromatosis Type 1 With Plexiform Neurofibromas
11/12/2024
According to a phase 2b trial, mirdametinib demonstrated significant confirmed objective response rates with deep and durable reductions of volume of target plexiform neurofibromas and clinically meaningful improvements to health-related...
According to a phase 2b trial, mirdametinib demonstrated significant confirmed objective response rates with deep and durable reductions of volume of target plexiform neurofibromas and clinically meaningful improvements to health-related...
According to a phase 2b trial,...
11/12/2024
Oncology
News
Epirubicin Plus Cyclophosphamide and Docetaxel Reduces Long-Term Risk of Recurrence for Patients With TOP2A Normal Early Breast Cancer
11/12/2024
According to final results from the DBCG 07-READ trial, the addition of epirubicin to cyclophosphamide and docetaxel reduced long-term risk of breast cancer recurrence among patients with TOP2A normal early breast cancer.
According to final results from the DBCG 07-READ trial, the addition of epirubicin to cyclophosphamide and docetaxel reduced long-term risk of breast cancer recurrence among patients with TOP2A normal early breast cancer.
According to final results from...
11/12/2024
Oncology
News
Pembrolizumab Plus Chemotherapy For Patients With High-Risk Endometrial Cancer
11/11/2024
According to results from a phase 3 trial, pembrolizumab plus chemotherapy did not improve DFS among patients with high-risk endometrial cancer. However, there may be a benefit among patients with mismatch report-deficient disease.
According to results from a phase 3 trial, pembrolizumab plus chemotherapy did not improve DFS among patients with high-risk endometrial cancer. However, there may be a benefit among patients with mismatch report-deficient disease.
According to results from a...
11/11/2024
Oncology
FDA Approval
FDA Grants Approval to Obecabtagene Autoleucel for R/R B-Cell Precursor Acute Lymphoblastic Leukemia
11/08/2024
On November 8, 2024, the FDA approved CD19-directed genetically modified autologous T cell immunotherapy obecabtagene autoleucel for the treatment of patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia.
On November 8, 2024, the FDA approved CD19-directed genetically modified autologous T cell immunotherapy obecabtagene autoleucel for the treatment of patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia.
On November 8, 2024, the FDA...
11/08/2024
Oncology
News
Naporafenib in Combination With Rineterkib or Tremetinib for KRAS- or BRAF-Mutant Non-Small Cell Lung Cancer
11/07/2024
While naporafenib plus rineterkib and naporafenib plus trametinib both had acceptable safety profiles, antitumor activity was limited among patients with KRAS-/BRAF-mutant non-small cell lung cancer.
While naporafenib plus rineterkib and naporafenib plus trametinib both had acceptable safety profiles, antitumor activity was limited among patients with KRAS-/BRAF-mutant non-small cell lung cancer.
While naporafenib plus...
11/07/2024
Oncology
News
Addition of Concurrent Thoracic Radiotherapy to First-Line TKI Therapy Improves Survival for Patients With EGFR-Mutated Non-Small Cell Lung Cancer
11/06/2024
According to results from a phase 3 trial, the addition of concurrent thoracic radiotherapy to first-line icotinib improved survival among patients with EGFR-mutated oligo-organ metastatic non-small cell lung cancer.
According to results from a phase 3 trial, the addition of concurrent thoracic radiotherapy to first-line icotinib improved survival among patients with EGFR-mutated oligo-organ metastatic non-small cell lung cancer.
According to results from a...
11/06/2024
Oncology
News
Ipilimumab After PD-1 Inhibition Failure Among Patients With Metastatic Melanoma
11/05/2024
A single-center real-world study found the use of ipilimumab in the second-line was an effective therapy for patients with metastatic BRAF/NRAS-wildtype metastatic melanoma without brain metastases.
A single-center real-world study found the use of ipilimumab in the second-line was an effective therapy for patients with metastatic BRAF/NRAS-wildtype metastatic melanoma without brain metastases.
A single-center real-world study...
11/05/2024
Oncology

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use